drugset / Trial / NCT06251388
A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer
Phase 2
Recruiting
50 enrolled
West China Second University Hospital
Affiliated Hospital of North Sichuan Medical College · collabThe Affiliated Hospital Of Southwest Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of concurrent chemoradiotherapy（CCRT）followed by cadonilimab（AK104) in high risk local advanced cervical cancer. Participants received CCRT，efficacy evaluation of CCRT was no disease progression who maintained with AK104（10.0 mg/kg，Q3W）until drug exposure over 1 years or disease progression or intolerable toxicity.
Timeline
- Start
- 2024-02-20
- Primary completion
- 2025-05-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |